Plaque Psoriasis Market Outlook
Plaque psoriasis impacts 2-3% of the global population, affecting approximately 6.7 million adults worldwide. In the United States, 1-2% of the population lives with this condition. Additionally, around 30% of psoriasis patients develop psoriatic arthritis. Plaque Psoriasis Drug Pipeline Analysis This high prevalence has prompted pharmaceutical companies and research institutions to prioritise the development of advanced, effective therapies, driving innovation and expanding the drug pipeline to better meet the needs of those with plaque psoriasis.
Get Free Sample Report with a Table of Contents:https://www.expertmarketresearch.com/clinical-trials/plaque-psoriasis-drug-pipeline-analysis/requestsample
Plaque Psoriasis: Introduction
Plaque psoriasis is a chronic autoimmune disorder where the immune system triggers the rapid buildup of skin cells, leading to red, scaly patches on the skin. These plaques often cause itching, pain, and discomfort, significantly affecting daily life. Common triggers include stress, infections, and genetic predisposition. Treatment options include topical agents, phototherapy, systemic drugs, and biologics targeting immune pathways. Early diagnosis and tailored therapies are vital for effective management. Ongoing research focuses on innovative treatments to address unmet needs and improve the quality of life for individuals with plaque psoriasis.
Plaque Psoriasis Treatment Overview
Plaque psoriasis is an inflammatory skin condition where the immune system triggers excessive skin cell production, resulting in thick, scaly plaques. It often has a relapsing course and can be influenced by environmental and genetic factors. The condition can significantly impact daily life and mental health, requiring long-term management.
Treatment options include topical therapies like corticosteroids and vitamin D analogues for mild cases. Moderate-to-severe cases may require phototherapy, systemic drugs, or biologics targeting specific immune pathways. Emerging therapies aim to provide more effective and personalised treatment with fewer side effects.
Read Full Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/plaque-psoriasis-drug-pipeline-analysis
Drug Pipeline Therapeutic Assessment
Analysis by Route of Administration
1. Oral
2. Parenteral
3. Others
Analysis by Phase
1. Preclinical Phase
2. Phase I
3. Phase II
4. Phase III
5. Phase IV
Analysis by Drug Class
- Antibody
- Antisense Oligonucleotides
- Immunotherapy
- Monoclonal Antibody
- Peptides
- Protein
- Recombinant Protein
- Small Molecule
- Stem Cell
- Vaccine
Plaque Psoriasis Drug Classes
Plaque psoriasis treatments utilise a range of drug classes, each designed to target specific pathways and mechanisms involved in cancer growth and survival. These diverse classes enhance the effectiveness of therapy and contribute to personalised treatment strategies. Understanding these drug classes is essential for optimising patient outcomes.
1. Antibody
Antibodies are immune system proteins engineered to target specific molecules involved in the inflammatory processes of plaque psoriasis. By neutralising these targets, they reduce immune system overactivity, alleviate symptoms like redness and scaling, and prevent future flare-ups. Antibody-based therapies offer precise treatment, particularly in patients who do not respond well to traditional medications.
2. Antisense Oligonucleotides
Antisense oligonucleotides are short DNA or RNA sequences designed to bind to specific genetic material and block the production of inflammatory proteins. This approach reduces immune-mediated damage and excessive skin cell production. Their ability to precisely target genetic pathways makes them a promising and innovative treatment option for managing plaque psoriasis.
3. Immunotherapy
Immunotherapy involves treatments that modify the immune response to reduce inflammation and slow excessive skin cell production. These therapies are especially effective in moderate-to-severe plaque psoriasis, helping to control symptoms and improve quality of life. Immunotherapies include biologics and other advanced medications that target specific pathways involved in the disease process.
4. Monoclonal Antibody
Monoclonal antibodies are laboratory-made proteins that specifically target immune system components, such as interleukins, to reduce inflammation in plaque psoriasis. They are particularly effective in severe cases, offering targeted and long-lasting treatment with minimal systemic side effects. These therapies provide a precise approach to controlling chronic symptoms.
5. Peptides
Peptides are short chains of amino acids that interact with specific immune pathways or promote skin regeneration. They help modulate the immune response, reducing inflammation and accelerating healing. Their high specificity and low toxicity make peptides a valuable addition to the range of therapies available for plaque psoriasis.
6. Protein
Protein-based drugs regulate immune system activity, helping to control the overproduction of skin cells and inflammation associated with plaque psoriasis. These therapies mimic natural proteins in the body, offering an effective and safe option for managing symptoms and preventing disease progression.
7. Recombinant Protein
Recombinant proteins are artificially engineered to replicate natural proteins that regulate immune activity. They are designed to reduce excessive inflammation and slow the rapid skin cell turnover characteristic of plaque psoriasis. This advanced approach offers precise symptom control with improved patient outcomes.
8. Small Molecule
Small molecules are chemically synthesised compounds that target specific enzymes or signalling pathways involved in inflammation. They are often used in oral treatments for moderate-to-severe plaque psoriasis, offering convenience and effectiveness in managing the underlying immune dysfunction driving the condition.
9. Stem Cell
Stem cell therapies aim to repair or replace damaged skin cells and modulate immune responses in plaque psoriasis. By regenerating healthy tissue and restoring immune balance, stem cells represent a cutting-edge, potentially curative approach to managing this chronic condition.
10. Vaccine
Vaccines for plaque psoriasis are under development to train the immune system to recognise and suppress inflammatory triggers. This innovative strategy aims to provide long-term control by preventing excessive immune responses and reducing the frequency and severity of flare-ups, offering hope for sustained disease remission.
Plaque Psoriasis- Pipeline Drug Profiles
This section provides an overview of the various drugs used in the treatment of plaque psoriasis. It covers their classifications, mechanisms of action, and methods of administration, offering essential insights for effective treatment strategies.
1. EDP1815
EDP1815 is an innovative oral treatment in development, derived from a single strain of commensal bacteria. It works by influencing gut-immune pathways to reduce systemic inflammation. This novel mechanism shows promise for treating plaque psoriasis, with early trials demonstrating notable skin improvements and a favourable safety profile, making it a potential breakthrough therapy.
2. AX-158
AX-158 is an investigational oral drug that modulates T-cell activity to address the immune dysfunction underlying plaque psoriasis. By reducing overactive immune responses, it aims to control symptoms effectively. Its distinct mechanism of action positions it as a promising therapy, with the added advantage of maintaining a strong safety profile during treatment.
3. Cetaphil
Cetaphil is a well-known topical product designed to hydrate and protect the skin, making it suitable for those with psoriasis-prone skin. Although it does not directly treat inflammation, it supports medical treatments by reducing dryness, itchiness, and irritation, helping to improve overall skin condition and comfort for patients.
Plaque Psoriasis: Competitor Landscape
The key features of the report include patent analysis, clinical trials, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Power Life Sciences Inc.
Based in the USA, Power Life Sciences Inc. is focused on developing targeted therapies for autoimmune and inflammatory conditions, including plaque psoriasis. Their pipeline includes innovative biologics and immunomodulators designed to address underlying immune dysfunction while improving patient quality of life.
Evelo Biosciences, Inc.
Headquartered in Cambridge, Massachusetts, USA, Evelo Biosciences develops therapies targeting the gut-immune axis. Their flagship product, EDP1815, is a breakthrough in treating inflammatory conditions like plaque psoriasis, with a focus on improving efficacy and safety through novel mechanisms of action.
Artax Biopharma Inc.
Based in Weston, Massachusetts, USA, Artax Biopharma specialises in immunomodulators for autoimmune diseases. Their research includes AX-158, a promising candidate for plaque psoriasis, aimed at reducing inflammation by targeting specific T-cell pathways. Artax’s commitment to precision medicine positions it as a leader in autoimmune treatment innovation.
Other key players in the landscape include Bristol-Myers Squibb, Dermavant Sciences, Inc., Alza Corporation, DE, USA, Arcutis Biotherapeutics, Inc., Shanghai Celgen Bio-Pharmaceutical Co., Ltd, Amgen, Novartis Pharmaceuticals, Huabo Biopharm Co., Ltd., and Galderma R&D.โฏโฏ
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
